Skip to main content

Table 4 Effect of doxycycline and placebo treatment on Wolbachia loads in larval worms: results quantitative PCR

From: Retarded Onchocerca volvulus L1 to L3 larval development in the Simulium damnosum vector after anti-wolbachial treatment of the human host

 

Mf (skin)

L1 (vector)

L2 (vector)

L3 (vector)

Month a

Doxy b

Placebo

Doxy

Placebo

Doxy

Placebo

Doxy

Placebo

0

7/7c

(0.06)d

5/5

(0.02)

7/7

(0.058)

4/5

(0.03)

e

e

6/6

(0.026)

5/5

(0.05)

1

6/7

(0.024)

4/4

(0.05)

4/7

(0.002)

5/5

(0.06)

e

e

3/7

(0.008)

5/5

(0.03)

2

2/6

(0.068)

5/5

(0.22)

0/6

5/5

(0.11)

1/6

(0.007)

4/5

(0.06)

2/6

(0.011)

5/5

(0.05)

3

2/7

(0.085)

4/4

(0.70)

2/7

(0.06)

5/5

(0.41)

4/7

(0.029)

5/5

(0.16)

4/7

(0.059)

5/5

(0.19)

4

3/7

(0.085)

5/5

(0.30)

0/7

4/4

(0.32)

3/7

(0.002)

4/4

(0.16)

2/7

(0.036)

5/5

(0.43)

5

1/7

(0.167)

5/5

(0.56)

3/7

(0.001)

3/3

(0.08)

1/7

(0.002)

4/4

(0.09)

3/6

(0.017)

5/5

(0.12)

  1. a Month after treatment
  2. b Treatment with Doxycycline (200 mg/day) for 6 weeks
  3. c Number of Wolbachia ftsZ positive volunteers
  4. d Median ftsZ/β-actin ratio
  5. e L1 and L2 counts were combined at months 0 and 1 of the study